ALS Drugs: Second US FDA Meeting On AMX0035 Gives Amylyx A Chance To Capitalize On Recent Events

Company is coming into its second panel meeting with new data analyses from the CENTAUR trial, advisory committee experience under its belt, and a recent Health Canada approval. In an interview with the Pink Sheet, co-CEOs Cohen and Klee highlight clinical outcomes data with AMX0035 and say they are not too worried about the lack of effect on neurofilament biomarker.

Second chance
Amylyx will get a second chance to make the case for its ALS drug to an FDA advisory committee. • Source: Shutterstock

In the eyes of Amylyx Pharmaceuticals, Inc. co-CEOs Josh Cohen and Justin Klee, a lot has happened since a US Food and Drug Administration advisory committee narrowly recommended against approval of the company’s amyotrophic lateral sclerosis drug in late March.

In the five-plus month interval between that meeting on AMX0035 and a planned second review by the Peripheral and Central...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers